
Gemelli Biotech: Pioneering non-invasive diagnostics and therapeutics to unlock the potential of the human microbiome.
Gemelli Biotech is a specialty biotechnology company founded with the mission to support the discovery of novel diagnostics and therapeutics for the human microbiome. The company's vision is to create a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemelli Biotech offers non-invasive precision diagnostics aimed at detecting scientifically validated biomarkers to optimally treat gastrointestinal diseases, including SIBO (Small Intestinal Bacterial Overgrowth), IMO (Intestinal Methanogen Overgrowth), excess hydrogen sulfide, and post-infectious IBS (Irritable Bowel Syndrome).
Notable affiliated individuals and investors include leading experts in microbiome research and biotechnology. The company has achieved significant milestones in developing and commercializing non-invasive diagnostic tests that have improved the accuracy and ease of diagnosing complex GI conditions. Gemelli Biotech's impact is evident in its contribution to advancing precision medicine, providing clinicians with tools to better understand and treat gastrointestinal diseases, ultimately improving patient outcomes and quality of life.

GenieBiome

Petri Bio
petribio.com

Envivo Bio
envivo.bio

Hera Biotech
herabiotech.com

Zymeron
zymeron.com

Novome Biotechnologies

Siolta Therapeutics

Gusto Global
gustoglobal.com

Geminii Health
geminiihealth.com

Precision IBD
Gema Diagnostics
gemadx.com

FloraSeq
Cobio Diagnostics
cobio.co

Molecular Biometrics

BiomeSense
biomesense.com
Companies similar to Gemelli Biotech include GenieBiome, Petri Bio, Envivo Bio and Hera Biotech.
Gemelli Biotech was founded in 2018.
Gemelli Biotech's headquarters is located in Raleigh, NC, US.
Gemelli Biotech's most recent funding round was for $19M (USD) in June 2022.
As of Jun 22, 2022, Gemelli Biotech has disclosed funding of $28.4M (USD). Undisclosed round amounts are excluded.
Gemelli Biotech has 2,525 employees as of Feb 5, 2024.